NeoPharm Co., Ltd.

NeoPharm Co., Ltd.

NeoPharm Co., Ltd.

Overview
Date Founded

2000

Headquarters

309-8 Techno 2-ro,Yuseong-gu,Daejeon 34037

Type of Company

Public

Employees (Worldwide)

87

Industries

Personal Products
Pharmaceuticals

Company Description

NeoPharm Co., Ltd. engages in the development, manufacture and sale of cosmetics and pharmaceutical products. It operates through the Cosmetics and Pharmaceuticals business divisions. The Cosmetics division provides emulsified and functional skin care products for sensitive and dry skin, treatment of atopic dermatitis and psoriasis, and therapy for steroid side effects. The Pharmaceutical business offers medical products for inflammatory skin diseases, diabetes and obesity treatment. The company was founded on July 1, 2000 and is headquartered in Daejeon, South Korea.

Website

http://www.neopharm.co.kr

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
Executives & Employees
See More
Dae-Yeol Lee

Chief Executive Officer & Director

Yoon Kim

Director & Head-Research Institute

Board of Directors
Dae-Yeol Lee

Former Chief Executive Officer & Director at NeoPharm Co., Ltd.

Yoon Kim

Director, MD & Head-Research & Production at NeoPharm Co., Ltd.

Gi-Young Hong

Independent Director at NeoPharm Co., Ltd.

Hak-Young Kim

Independent Director at NeoPharm Co., Ltd.

Trending People
US Consumer Product Safety Commission
After child dies, US regulator warns about Peloton treadmill - Associated Press
Federal Aviation Administration
Northwest Bayside Civic Association Issues Public Comment on FAA Notice on Aircr... - Targeted News Service
Supreme Court of the United States
Coalition to Promote Independent Entrepreneurs Issues Public Comment on Wage & H... - Targeted News Service
Rosen~Harbottle
AQST INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aq... - PR Newswire
Rosen Law Firm
AQST INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aq... - PR Newswire
Trending Organizations
US Consumer Product Safety Commission
After child dies, US regulator warns about Peloton treadmill - Associated Press
Federal Aviation Administration
Northwest Bayside Civic Association Issues Public Comment on FAA Notice on Aircr... - Targeted News Service
Supreme Court of the United States
Coalition to Promote Independent Entrepreneurs Issues Public Comment on Wage & H... - Targeted News Service
Rosen~Harbottle
AQST INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aq... - PR Newswire
Rosen Law Firm
AQST INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aq... - PR Newswire
Paths to NeoPharm Co., Ltd.
Potential Connections via
Relationship Science
You
NeoPharm Co., Ltd.
Recent Transactions
Details Hidden

Hanbul Cosmetics Co., Ltd. purchases NeoPharm Co., Ltd.

Details Hidden

Hanbul Cosmetics Co., Ltd. purchases NeoPharm Co., Ltd.

Details Hidden

NeoPharm Co., Ltd. issued Ordinary Shares

Transaction Advisors
Underwriter
Samsung Securities Co., Ltd. (Broker)

Advised onNeoPharm Co., Ltd. issued Ordinary Shares
Clients
Sa Sa International Holdings Ltd.

Sa Sa International Holdings Ltd. is investment company, which engages in the retailing and wholesaling of cosmetic products. Its products include skin care, fragrance, make-up, body care and hair care as well as health food. It operates through the following segments: Hong Kong and Macau, Mainland China, E-commerce, and All Other segments. The All Other segments refers to markets in Singapore and Malaysia. The company was founded by Kwai Chun Kwok Law in 1978 and is headquartered in Hong Kong.
Key Stats and Financials As of 2018
Market Capitalization
$398B
Total Enterprise Value
$280B
Earnings Per Share
$2,173
Revenue
$66.3B
Net Profit
$15.4B
EBITDA
$20B
EBITDAMargin
30.17%
Total Debt
$400M
Total Equity
$59.3B
Enterprise Value Sales
4.22x
Enterprise Value EBITDAOperating
13.99x
TEVNet Income
18.2x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
22.6%
Five Year Compounded Annual Growth Rate Of Revenue
26.9%

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by NeoPharm Co., Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of NeoPharm Co., Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and NeoPharm Co., Ltd..